GMP Final Rule Takes Effect

Rockville, MD (Dec. 4)-FDA's Final Rule titled “Amendments to the Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals” will take effect on Monday, Dec. 8, 2008. As the “culmination of the first increment of modifications to [CFR] parts 210 and 211,” the rule revises CGMP requirements primarily for aseptic processing, the use of asbestos filters, and the verification of performance operations by a second individual.

Regarding aseptic processing, the rule revises CFR section 211.113(b), which now clarifies that the required written procedures to prevent microbial contamination of sterile drug products must include procedures for the validation of all aseptic processes in addition to sterilization processes. The rule also revises CFR section 211.84(d)(6), requiring that microbiological testing be conducted before the use of each lot of component, drug product, or closure “with potential for microbiological contamination.” CFR section 211.94(c), regarding the depyrogenation process for drug-product containers, and CFR section 211.110(a), regarding bioburden testing of in-process control procedures and materials, are also revised.

The final rule revises CFR section 210.3(b)(6) and 211.72 to eliminate provisions that permitted limited use of asbestos-containing filters during the processing of injectable drug products. The regulations now include the statement, “The use of an asbestos-containing filter is prohibited.”